Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 13/20 | 0.78 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.71 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.71 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.71 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.71 |
| ▸ | PRKDC | P78527 | 2/20 | 0.71 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.71 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.71 |
| ▸ | PIK3R5 | Q8WYR1 | 2/20 | 0.71 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.71 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.67 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.67 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.67 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855515 | 0.88 | PIK3CA (1.00) | MTORPIK3CAPIK3CGPIK3CDPIK3C2B | |
| SCHEMBL1310735 | 0.85 | PIK3CA (0.57) | MTORPIK3CAPIK3CGPIK3CDPIK3C2B | |
| SCHEMBL7914669 | 0.84 | MTOR (0.81) | MTORPIK3CAPIK3CGPIK3CDPIK3C2B | |
| SCHEMBL1310732 | 0.83 | MTOR (0.76) | MTORPIK3CAPIK3CGPIK3CDPIK3C2B | |
| Buparlisib SCHEMBL29350945 | 0.83 | MTOR (1.00) | MTORPIK3CAPIK3CGPIK3CDPIK3C2B | |
| Buparlisib SCHEMBL29387968 | 0.83 | MTOR (1.00) | MTORPIK3CAPIK3CGPIK3CDPIK3C2B | |
| Buparlisib SCHEMBL146956 | 0.83 | MTOR (1.00) | MTORPIK3CAPIK3CGPIK3CDPIK3C2B | |
| Buparlisib SCHEMBL29351351 | 0.83 | MTOR (1.00) | MTORPIK3CAPIK3CGPIK3CDPIK3C2B | |
| Buparlisib SCHEMBL18528952 | 0.82 | MTOR (0.98) | MTORPIK3CAPIK3CGPIK3CDPIK3C2B | |
| Buparlisib SCHEMBL143412 | 0.82 | MTOR (0.98) | MTORPIK3CAPIK3CGPIK3CDPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766874-B2 | Manufacturing process for triazine, pyrimidine and pyridine derivatives | UNIVERSITAET BASEL (CH) | 2020-09-08 | — | — | US | disclosed |
| US-10766874-B2 | Manufacturing process for triazine, pyrimidine and pyridine derivatives | UNIVERSITAET BASEL (CH) | 2020-09-08 | — | — | US | disclosed |
| CN-111032085-A | Combination of an immune checkpoint antagonist and a RANK-L (NF-KB ligand) antagonist or bispecific binding molecules thereof for use in cancer treatment or prevention and uses thereof | 昆士兰医学研究所理事会 | 2020-04-17 | — | — | CN | disclosed |
| US-20190016698-A1 | NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES | TORQUR AG (CH) | 2019-01-17 | — | — | US | disclosed |
| US-20190016698-A1 | NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES | TORQUR AG (CH) | 2019-01-17 | — | — | US | disclosed |
| EP-3134388-B1 | NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES | UNIV BASEL (CH) | 2019-01-09 | — | — | EP | disclosed |
| EP-3134388-B1 | NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES | UNIV BASEL (CH) | 2019-01-09 | — | — | EP | disclosed |
| US-10100031-B2 | Manufacturing process for triazine, pyrimidine and pyridine derivatives | UNIVERSITAET BASEL (CH) | 2018-10-16 | — | — | US | disclosed |
| EP-3134388-A1 | NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES | Universität Basel (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-20170037027-A1 | NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES | TORQUR AG (CH) | 2017-02-09 | — | — | US | disclosed |
| WO-2015162084-A1 | NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES | UNIVERSITAET BASEL (CH) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015162084-A1 | NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES | UNIVERSITAET BASEL (CH) | 2015-10-29 | — | — | WO | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016698-A1 | NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES | IL5, WIZ, TPMT | MTOR 2001/4885PIK3CA 1654/4885PIK3CG 1659/4885 |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | MTOR 1/4885PIK3CA 2/4885PIK3CG 16/4885 |
| US-10100031-B2 | Manufacturing process for triazine, pyrimidine and pyridine derivatives | IL5, WIZ, TPMT | MTOR 1914/4885PIK3CA 1453/4885PIK3CG 1510/4885 |
| US-20170037027-A1 | NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES | IL5, WIZ, TPMT | MTOR 2042/4885PIK3CA 1580/4885PIK3CG 1650/4885 |
| US-10766874-B2 | Manufacturing process for triazine, pyrimidine and pyridine derivatives | IL5, WIZ, TPMT | MTOR 2151/4885PIK3CA 1298/4885PIK3CG 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.